


PRODUCT INFORMATION



Risedronate (sodium salt)

Item No. 20740

CAS Registry No.: 115436-72-1
Formal Name: P,P'-[1-hydroxy-2-(3-pyridinyl)ethylidene] bis-phosphonic acid, monosodium salt
MF: C₇H₁₀NO₇P₂ • Na
FW: 305.1
Purity: ≥95%
UV/Vis.: λ_{max}: 262 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Risedronate (sodium salt) is supplied as a crystalline solid. Aqueous solutions of risedronate (sodium salt) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of risedronate (sodium salt) in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Risedronate is a heterocyclic orally active aminobisphosphonate.¹ Like other bisphosphonates, it inhibits bone resorption.^{1,2} In addition, it has antimalarial activity and inhibits growth of *P. falciparum* *in vitro* (IC₅₀ = 20.3 μM) and *P. berghei* *in vivo* (25 mg/kg for one week).³ It also inhibits protein prenylation by preventing the transfer of a farnesyl pyrophosphate group to parasite proteins. Formulations containing risedronate have been used to reduce fracture risk in both age- and steroid-related osteoporosis.^{1,2,4}

References

1. Nuti, R. Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis. *Clin. Cases Miner. Bone Metab.* **11(3)**, 208-214 (2014).
2. Lems, W.F. and den Heijer, M. Established and forthcoming drugs for the treatment of osteoporosis. *Neth. J. Med.* **71(4)**, 188-193 (2013).
3. Jordao, F.M., Saito, A.Y., Miguel, D.C., *et al.* *In vitro* and *in vivo* antiplasmodial activities of risedronate and its interference with protein prenylation in *Plasmodium falciparum*. *Antimicrob. Agents Chemother.* **55(5)**, 2026-2031 (2011).
4. Pereira, R.M.R., de Carvalho, J.F., Paula, A.P., *et al.* Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. *Rev. Bras. Reumatol.* **52(4)**, 580-593 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM